Clinical trials: Incretins
Insulin Secretion
Incretin Action in Physiology and Diabetes
This project is designed to advance understanding of the incretin effect in health and disease. This system of gut-islet linkage is essential for normal glucose tolerance, impaired in T2DM, and amenable to therapeutic…
- Trial name
- NCT02550548
- Testing
- GIP infusion, GLP-1 infusion, Ex-9 infusion
- Where
- United States
- Volunteers
- 39 people, healthy volunteers welcome
- Sponsor
- David D'Alessio, M.D.
Diabetes Mellitus, Gastroparesis
Drug Trial of Lixisenatide on Gastric Emptying and Blood Pressure Drops in Type 2 Diabetics and Healthy People
The purpose of this study is to determine the effects of the drug lixisenatide on blood sugar levels, stomach emptying, blood pressure and heart rate, release of gut hormones and blood flow in the gut after a glucose drink in…
- Trial name
- Lixi (NCT02308254)
- Testing
- Lixisenatide
- Where
- Australia
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Royal Adelaide Hospital
Gastric Bypass Surgery, Obesity
Mechanisms of Diabetes Control After Weight Loss Surgery
Obesity and type 2 diabetes (T2DM) are increasing in the US. One third of patients seeking bariatric surgery have T2DM. Although all surgeries result in significant weight loss and often 'cure' the T2DM, the rapid onset and the…
- Trial name
- NCT00571220
- Testing
- gastric bypass surgery, Diet induced weight loss
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Overweight , Obesity, Adults
Study to Assess the Effect and Safety of ALV-100 on Maintenance of Weight Loss
A study of ALV-100 to assess efficacy, safety and tolerability among participants with overweight or obesity who have previously achieved a body weight reduction of ≥10% while treated with incretin-based therapies.
- Trial name
- PRESERVE (NCT07837973)
- Testing
- ALV-100
- Where
- 20 sites in United States
- Volunteers
- 220 people
- Sponsor
- Alveus Therapeutics, Inc.
Hyperlipidemias, Nutritional and Metabolic Diseases
Lean Seafood Intake and Postprandial Metabolism
Despite numerous studies of meal components in humans, little is still known about how different meals influence on metabolism. The purpose of this study is to a gain knowledge of how a balanced test meal with either lean seafood…
- Conditions
- Hyperlipidemias, Nutritional and Metabolic Diseases, Nutrition Disorders, Metabolic Diseases
- Trial name
- LeSIP (NCT01708681)
- Testing
- Lean seafood, Meat, egg, milk
- Where
- Norway
- Volunteers
- 27 people, healthy volunteers welcome
- Sponsor
- National Institute of Nutrition and Seafood Research, Norway
Diabetes, Hyperglycemia
Insulin Secretion in Diabetes Before and After Glycemic Control
The objective of this project is to understand defects in insulin secretion that contribute to abnormal glucose metabolism in patients with diabetes.
- Trial name
- NCT00469833
- Testing
- insulin glargine
- Where
- United States
- Volunteers
- 17 people, healthy volunteers welcome
- Sponsor
- US Department of Veterans Affairs
Diabetes
Quantification of the Dipeptidyl Peptidase (DPP)-4 Inhibition-mediated Enhancement of the Activity of the Entero-insular Axis
Objective: To assess the effect if co-administration of sitagliptin and metformin compared to placebo on the incretin effect (based on the comparison of the insulin secretory response to oral glucose load and an 'isoglycaemic'…
- Trial name
- NCT00683735
- Testing
- Sitagliptin, Metformin
- Where
- Germany
- Volunteers
- 20 people
- Sponsor
- Michael A. Nauck
Diabetes Mellitus, Type 1
Meal-time Administration of Exenatide for Glycaemic Control in Type 1 Diabetic Cases
Patients with type 1 diabetes (T1D) depend on insulin therapy as substitution for the lack of endocrine insulin production due to an autoimmune destruction of beta-cells in the pancreatic inslets.
- Trial name
- MAG1C (NCT03017352)
- Testing
- Exenatide
- Where
- Denmark
- Volunteers
- 108 people
- Sponsor
- Filip Krag Knop
Obesity, Overweight
A Study to Investigate the Effect of LY4086940 Versus Placebo in Participants With Obesity or Overweight and Without Type 2 Diabetes
The purpose of this study, performed under the master protocol W8M-MC- CWMM (NCT06143956), is to evaluate the efficacy and safety of LY4086940 compared with placebo in participants without type 2 diabetes who have obesity or who…
- Trial name
- NCT07890376
- Testing
- LY4086940
- Where
- 46 sites in United States, Argentina
- Volunteers
- 460 people
- Sponsor
- Eli Lilly and Company
Obesity
Estimating the Impact of Obesity Medications on Clinical and Economic Outcomes
The goal of this observational study is to identify the impact of incretin-based obesity medications (e.g., GLP-1 and GLP-1/GIP) on health and economic outcomes among adults who get their health insurance through their employers.
- Trial name
- NCT07640139
- Testing
- Incretin-based therapies (GLP-1 and GLP-1/GIP)
- Where
- United States
- Volunteers
- 125,000 people
- Sponsor
- Indiana University
Obesity, Morbid, Diabetes Mellitus, Type 2
Jejunal Ketogenesis and Type 2 Diabetes
The goal of this cross-over study in obese subjects is to learn about the common co-morbidity type 2 diabetes and the local formation of ketone bodies.
- Conditions
- Obesity, Morbid, Diabetes Mellitus, Type 2, Intestines, Incretins
- Trial name
- But2 (NCT05767177)
- Testing
- Glucemia following Mixed Meal Test, Enteroscopy - mucosal ketogenic activity as well as glucose transport
- Where
- Sweden
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Göteborg University
GLP-1, Obesity &Amp; Overweight
Effect of a Dietary Supplement on Hormones Involved in Appetite Regulation in Overweight and Obese Adults
Obesity is a chronic condition linked to numerous health risks and affects more than one billion people worldwide. While pharmacological treatments such as incretin-based therapies are available, they may have side effects, are…
- Conditions
- GLP-1, Obesity &Amp; Overweight, Dietary Supplement
- Trial name
- NCT07240246
- Testing
- Intervention: Dietary Supplement with Plant Extracts
- Where
- Austria
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- FFoQSI - Austrian Competence Centre for Feed and Food Quality, Safety & Innovation
ESRD
Glucose Metabolism During Hemodialysis
Disturbed glucose metabolism is a common feature of patients with end-stage renal disease (ESRD). Several hormones responsible of a stable blood glucose including insulin, glucagon, and the gastrointestinal insulinotropic…
- Trial name
- NCT01800188
- Testing
- Hemodialysis, Hemodiafiltration, Meal test
- Where
- Denmark
- Volunteers
- 10 people
- Sponsor
- Bo Feldt-Rasmussen
Type 2 Diabetes
Sitagliptin in the Elderly
Diabetes is common in the elderly; by the age of 70, approximately 25% of the population will have diabetes. Unfortunately, currently available medications are often not as effective or not well tolerated in older adults.
- Trial name
- NCT00451113
- Testing
- Sitagliptin 100 mg
- Where
- Canada
- Volunteers
- 12 people
- Sponsor
- University of British Columbia
Type 2 Diabetes Mellitus
Effect of Sitagliptin on Incretin Effect in Patients With Type 2 Diabetes Mellitus
The purpose of this study is to assess the effect of the DPP-4 inhibitor sitagliptin on the incretin effect in patients with type 2 diabetes mellitus.
- Trial name
- NCT00551590
- Testing
- Sitagliptin tablet, Saline infusion, Exendin(9-39) infusion
- Where
- Germany
- Volunteers
- 24 people
- Sponsor
- Ludwig-Maximilians - University of Munich
GLUCOSE METABOLISM, DIABETES
Investigating Predictive Factors of Diabetes Occurence After Duodenalpancreatectomy
Regeneration of mature cells that produce functional insulin represents a major focus of current diabetes research aimed at restoring beta cell mass in patients with most forms of diabetes.
- Conditions
- GLUCOSE METABOLISM, DIABETES, PANCREATIC ISLETS, Exocrine Pancreatic Dysfunction
- Trial name
- NCT02175459
- Where
- Italy
- Volunteers
- 100 people
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Type 2 Diabetes
Sitagliptin and Glucagon Counterregulation
To evaluate the effect of DPP-4 inhibition on glucagon counter-regulatory mechanisms at moderate hypoglycemia in metformin-treated subjects with T2DM
- Trial name
- SITACLAMP (NCT02256189)
- Testing
- Sitagliptin
- Where
- Sweden
- Volunteers
- 28 people
- Sponsor
- Lund University
Pre-diabetes, Diabetes
Immediate and Long-term Induction of Incretin Release by Artificial Sweeteners 1
Epidemiological data suggest, that not only sugar-based, but also artificially sweetened soft drinks may play a role in the development of diabetes.
- Trial name
- ILIAS-1 (NCT02459535)
- Testing
- oral stimulation glucose, oral stimulation saccharin, oral stimulation aspartame
- Where
- Germany
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- German Institute of Human Nutrition
Obesity; Drug
Nutritional Therapy to Incretin-based Anti-obesity Medications in the Management of Gastrointestinal Adverse Events
The goal of the study is to evaluate the effect of nutrition intervention on gastrointestinal symptoms, treatment discontinuation rate, nutritional parameters (e.g., dietary intake and eating habits), anthropometric measures…
- Trial name
- NCT06431308
- Testing
- nutritional intervention
- Where
- 3 sites in Israel
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Ariel University
Diabetes Mellitus, Type 2, Insulin Resistance
Characterization of the Incretinpathy in Type 2 Diabetes Initiated After Sixty Years Old
Type 2 diabetes (T2DM) is characterized by hyperglycemia, insulin resistance, absolute or relative insulin deficiency, hyperglucagonemia, increased hepatic glucose production, frequently accelerated gastric emptying and obesity.
- Trial name
- NCT00843232
- Where
- Brazil
- Volunteers
- 24 people
- Sponsor
- University of Campinas, Brazil